August 7th 2023
The trial is expected to include 14 individuals with genetically confirmed limb-girdle muscular dystrophy who will be randomly assigned 1:1 to either AB-1003 or placebo for a year-long treatment period.
February 20th 2023
Clinician Perspectives on Black History Month: Adys Mendizabal, MD
February 17th 2023To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.
Clinician Perspectives on Black History Month: Larry Charleston IV, MD, MSc, FAHS
February 15th 2023To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.
Clinician Perspectives on Black History Month: Jon Cokley, PharmD, BCPPS
February 13th 2023To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.
VY-AADC01 Gene Therapy Demonstrates Safety, Improved Motor Function in Phase 1 Trial
October 22nd 2021The trial provided Class IV evidence that VY-AADC01 and the associated surgical delivery procedure were well-tolerated in patients aged 40 to 70 years with moderately advanced Parkinson disease.
scAAV9 Gene Therapy Safe, Effective in Preclinical Study in Epileptic SLC13A5 Deficiency
May 13th 2021The safety profile of the SLC13A5 vector was “excellent” according to study authors, with no adverse effects on weight, general activity, or survival in knockout mice and wild type littermates.
Treatment Disparities, Neurologic Complications Clarified by COVID-19 Neurological Research
April 19th 2021The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.